<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590808</url>
  </required_header>
  <id_info>
    <org_study_id>1806-088-951</org_study_id>
    <nct_id>NCT03590808</nct_id>
  </id_info>
  <brief_title>Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor</brief_title>
  <official_title>Efficacy and Safety of Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate efficacy and safety of influenza vaccine in cancer
      patients receiving immune checkpoint inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Solid cancer patients receiving immune checkpoint inhibitor or cytotoxic chemotherapy
           will be recruited 1:2 manner in two hospitals. Target numbers are 48 and 95,
           respectively.

        -  All the participants will be vaccinated for influenza during their chemotherapy when
           they meet inclusion criteria.

        -  All the participants will be asked if they have any contraindication for influenza
           vaccine by a physician before vaccination.

        -  Hemagglutination inhibition Ab titre at pre-vaccination and post-vaccination (21-35 days
           after vaccination) will be examined in all participants to examine seroprotection rates,
           seroconversion rates, and changes in geometric mean titer.

        -  And they will be monitored for any vaccination-related adverse reaction or
           immune-related adverse events after 2-4 days(via phone call), and till 6 months after
           vaccination (when they visit oncology clinics).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double center prospective case-control clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>21 to 35 days after vaccination</time_frame>
    <description>The percentage of vaccine recipients with a serum haemagglutination inhibition(HI) titre ≥40 post vaccination (21-28 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>21 to 35 days after vaccination</time_frame>
    <description>Seroconversion rate is defined as the percentage of vaccine recipients with a fourfold increase or more in post-vaccination HI titre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of HI</measure>
    <time_frame>21 to 35 days after vaccination</time_frame>
    <description>Geometric mean titers of HI (haemagglutination inhibition) after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection-related adverse events</measure>
    <time_frame>21 to 35 days after vaccination</time_frame>
    <description>The proportion of patients who experienced local or systemic adverse events related to vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-related adverse events</measure>
    <time_frame>6 months after vaccination</time_frame>
    <description>The proportion of patients who experienced immune checkpoint inhibitor induced immune-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell mediated immune response</measure>
    <time_frame>21 to 35 days after vaccination</time_frame>
    <description>The levels of intracellular cytokines measured by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Influenza</condition>
  <condition>Solid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Immune checkpoint inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solid cancer patients who receiving immune checkpoint inhibitor patients
will be undergone &quot;Influenza vaccination&quot; using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytotoxic chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solid cancer patients who receiving conventional cytotoxic chemotherapy
will be undergone &quot;Influenza vaccination&quot; using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccination</intervention_name>
    <description>Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM</description>
    <arm_group_label>Cytotoxic chemotherapy</arm_group_label>
    <arm_group_label>Immune checkpoint inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid cancer patients receiving immune checkpoint inhibitor or cytotoxic
             chemotherapeutic agent in Seoul National University Hospital or Seoul National
             University Bundang Hospital.

          -  Patients who was not vaccinated for influenza in 2018-2019 season

          -  ECOG performance status 0 or 1

          -  Patients who fulfilling following laboratory criteria Total bilirubin ≤ 1.5 x upper
             normal limit Aspartate transaminase, alanine transaminase ≤ 2.5 x upper normal limit
             Alkaline phosphatase ≤ 2.5 x upper normal limit Creatinine ≤ upper normal limit

          -  Patients who can understand and agreed with the informed consents.

        Exclusion Criteria:

          -  Patients having contraindication for influenza vaccination (e.g. egg allergy)

          -  Patients who receive any immunosuppressant (excluding steroid for anti-emetic effect)

          -  Patients with HIV infection

          -  Patients with autoimmune disease who are anticipated to have a problem with
             immunogenicity for vaccine

          -  Patients who have transplanted organ and receive immunosuppressants

          -  Patients who are suspected to have active infection (e.g. pneumonia)

          -  Patients who receive targeted chemotherapeutic agent alone for cancer treatment

          -  Patients who could not receive cancer chemotherapy due to hematologic abnormality at
             the date of the participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan Beom Park, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. Review.</citation>
    <PMID>29320654</PMID>
  </reference>
  <reference>
    <citation>Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.</citation>
    <PMID>28596256</PMID>
  </reference>
  <reference>
    <citation>Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Apr;15(4):504-535.</citation>
    <PMID>28404761</PMID>
  </reference>
  <reference>
    <citation>Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jun;15(6):804-834. doi: 10.6004/jnccn.2017.0100.</citation>
    <PMID>28596261</PMID>
  </reference>
  <reference>
    <citation>Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Kim NJ, Heo DS, Park WB, Oh MD. Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer. 2017 Mar 1;123(5):841-848. doi: 10.1002/cncr.30468. Epub 2016 Dec 20.</citation>
    <PMID>27997703</PMID>
  </reference>
  <reference>
    <citation>Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62. Erratum in: MMWR Recomm Rep. 2010 Aug 13;59(31):993. MMWR Recomm Rep. 2010 Sep 10;59(35):1147.</citation>
    <PMID>20689501</PMID>
  </reference>
  <reference>
    <citation>Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010 May 10;28(14):2481-90. doi: 10.1200/JCO.2009.26.6908. Epub 2010 Apr 12. Review.</citation>
    <PMID>20385981</PMID>
  </reference>
  <reference>
    <citation>Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.</citation>
    <PMID>26270597</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Wan Beom Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>solid carcinoma</keyword>
  <keyword>immune checkpoint</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are not planning to share IPDs publically, but de-identified individual participant data for all outcome measures could be shared with other researchers under their request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

